News

Back

Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug for the treatment of gastrointestinal inflammatory disorders and cancer.

January 12th 2022

BSCB Dev

Epics Therapeutics S.A., a private drug development company, announced today the initiation of a First-in-Human, double-blind, placebo-controlled, single and multiple ascending dose study of EP282 to evaluate oral pharmacokinetics, pharmacodynamics, safety and tolerability in healthy male volunteers. Specific biomarkers will also be monitored to evaluate drug-target engagement at different dose levels. Successful completion of this Phase I study will enable the initiation of Proof-of-Concept Phase II studies of EP282 in patient suffering from gastrointestinal inflammatory disorders as well as establish dose levels for initial clinical evaluation for specific types of cancer. Phase II studies are projected to start mid-2023. 

Read Pdf